Floatz logo

Therapeutic Asset Ratings

615 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Sorafenib
Immunotherapy
Fudan UniversityP2CCC (51)
Spironolactone
Metastatic Prostate Cancer
Fudan UniversityP2CCC (51)
T-Dxd
Radiotherapy
Fudan UniversityP2CCC (51)
Tifcemalimab
Nonpapillary Renal Cell Carcinoma
Fudan UniversityP2CCC (51)
Vebreltinib
Neoadjuvant Therapy
Fudan UniversityP2CCC (51)
Vesanoid
Triple-Negative Breast Carcinoma
Fudan UniversityP2CCC (51)
hr070803
Pancreatic Neoplasm
Fudan UniversityP3CCC (50)
Lornoxicam
Breast Cancer
Fudan UniversityP3CCC (50)
Iparomlimab
Ovarian Cancer
Fudan UniversityP2CCC (50)
N-Acetyl-L-Cysteine
Breast Cancer
Fudan UniversityP2CCC (50)
Shr-8068
Colorectal Cancer
Fudan UniversityP2CCC (50)
Shr-A2009
Breast Cancer
Fudan UniversityP2CCC (50)
PEG LOXENATIDE
Obesity Disorder
Fudan UniversityP2/3CCC (50)
Parsaclisib
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Fudan UniversityP1/2CCC (49)
9mw2821
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
9mw2821
HER2 Positive Breast Carcinoma
Fudan UniversityP2CCC (48)
Adebelimab
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
Adebelimab
HER2 Positive Breast Carcinoma
Fudan UniversityP2CCC (48)
Benmelstobart
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
Benmelstobart
HER2 Positive Breast Carcinoma
Fudan UniversityP2CCC (48)
bp102
Metastatic Malignant Neoplasm In The Colon
Fudan UniversityP2CCC (48)
Carboplatin
Colorectal Cancer Metastatic
Fudan UniversityP2CCC (48)
Catequentinib
HER2 Positive Breast Carcinoma
Fudan UniversityP2CCC (48)
ETOPOSIDE
Colorectal Cancer Metastatic
Fudan UniversityP2CCC (48)
Famitinib
HER2 Positive Breast Carcinoma
Fudan UniversityP2CCC (48)
Showing 451 to 475 of 615 assets
PreviousPage 19 of 25Next